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A comparative study of Japanese and US accounting for M & A 
- On the occasion of stock transfer 
of Daiichi Sankyo Company, Limited. — 
Yujiro Okura 
The subject of this study is to analyze a case to find what 
sort of effects reorganizations such as a merger, business 
transfer, company spin-off, and stock transfer will have on 
the laws and regulations of that country (Company Law in 
Japan, Securities and Exchange Law, tax law and 
accounting) and those of other relevant countries (SEC, IRC 
and FASB) for the controlling company (surviving company) 
& the controlled company (extinguishing company) 
themselves and their shareholders (corporations and 
individuals). We used an organizational act similar to a 
merger by means of the creation of the complete relationship 
of a parent and its subsidiary by a stock exchange of Daiichi 
Sankyo, as a material for this purpose 1. I studied Joint 
Share Transfer of Shares of Daiichi Pharmaceutical Co., 
Ltd. and Sankyo Company, Limited for shares of Daiichi 
Sankyo Company, Limited, 2000. This paper is the fruit of 
the study .Daiichi Pharmaceutical and Sankyo merged in 
the pooling of interest method in September 2005. However, 
because the foreign ownership of Daiichi Sankyo Company, 
Limited is high at 32. 7%, it was necessary to submit Form 4 
to SEC in June 20052. We carried out a comparative study 
of accounting in Japan and the USA centering on the 
difference between the pooling of interest method and the 
purchase method, using this as the material for the study. 
Keywords: Merger, business transfer, company spin-off, stock 
transfer, internationalization, purchase method, pooling of 
interest method, US accounting standards, Japanese 
accounting standards, provisional accounting, and 
goodwill 
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1. Precedent studies 
Multinational companies are required to prepare two kinds of 
financial statements in many cases. 
As precedent studies of comparative studies of Japanese and the 
US accounting, there are studies on the difference and analysis of its 
effect3 3 on 25 Japanese corporations which announce consolidated 
results at SEC. 
Mar. 1996 Mar. 1997 
{The number of companies) 
Consolidated PBT based on SEC standards is greater than 
22 24 
Consolidated PBT based on Japanese accounting standards: 
Consolidated PBT based on SEC standards is smaller than 
1 1 
Consolidated PST based on Japanese accounting standards: 
Impossible to decide due to different contents being inadequate: 2 ゜Mar. 1996 Mar. 1997 
Consolidated PBT on SEC standards (23 cos) (25 cos) 
2,008,811 3,038,424 
mil. Yen mil. Yen 
Consolidated PBT on Japanese accounting standards 1,830,726 2,744,209 
PBT on non-consolidated basis (individual co) 1,168,294 1,431,632 
Con/non-con ratio: Con PBT on SEC standards 1.72x 2.12x 
Con PBT on Japanese accounting standard 1.57 1.92 
Enterprise tax is a charge on profit, but at the time of this analysis it 
was accounted for as general administrative expenses under the old 
Japanese standards. The above results were on this basis. If the 
figures are amended on the basis of the Japanese standards currently 
in force where enterprise tax is included in corporation tax, etc., 
consolidated profit before tax under the Japanese accounting 
standards for the year ending March 1997 will be 3,063,906 million 
yen, and the con/non-con ratio will increase from 1.92x to 2.14x, 
which is greater than 1.12x of the con/non-con ratio under the SEC 
accounting standards. It will therefore be reversed. The major 
differences between the Japanese standards and the US standards 
as at this time were translation of items of financial statements of 
overseas subsidiaries under the Japanese standards (modified 
temporal method), non-adoption of the transaction method of lease 
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accounting, retirement money pension liabilities and pension 
expenses being not accounted for, deferred assets of test and 
research expenses, accounting for the impairment of long-term assets 
not being applied, non-adoption of tax effect accounting, and non-
adoption of the actual result standards of the provision for doubtful 
accounts. 
2. The difference between the Japanese standards and the US 
standards in the business combinations accounting 
(1) Purchase method and pooling of interest method 
1) Grounds for the adoption of purchase method 
In the USA, a business combination occurs, when an entity 
acquires the equity interests of another or more than one entity or 
acquires net assets comprising the business, and acquires the control 
of these other entities4. We have therefore decided that al business 
combinations made in accordance with the requirements of FAS141 
should be accounted for in the purchase method5. 
The first stage to apply the purchase method is the decision by the 
acquiring entity as the enterprise which will issue equity interests in 
the business combination which will have an effect through the 
exchange of the equity interests. The acquiring entity is the combining 
business which will pay a premium which is the excess of the market 
value of the equity interests of another combining business or entity 
during the period of the exchange of the controlling interests互Then,
goodwill will occur. 
The following points are the reason why the pooling of interest method 
does not provide information provided by the purchase method and 
no superior information to the purchase method is provided in any 
situation. 
Firstly, in the pooling of interest method al assets and liabilities of the 
merged company by a merger are not fair values as at the merger 
date, but are recognized at the pre-merger book values. Users of the 
financial statements of the enterprise after the merger cannot 
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reasonably evaluate the nature of future cash flow expected to arise 
from the amalgamated company and an increase in the value of 
profits as a result of the merger. 
Secondly, the accounting treatment in the purchase method is under 
general principles that fair values shall be applied to items that will be 
exchanged for merger transactions. On the other hand, operators will 
be unable to be responsible for their accountability concerning the 
investment that they made and the . results after that with the 
information provided by application of the pooling of interest method7. 
2) Grounds for the adoption of the pooling of interest method 
There are three requirements concerning the combination of 
interests under the business combination accounting standards in 
Japan, and the pooling of interest method may be adopted by fulfilling 
them. The stock transfer in this case satisfies al these requirements. 
Firstly, as a requirement for the consideration, al considerations paid 
on the business combination must be equities with voting rights in 
principle. 
Secondly, as a requirement for the ratio of voting rights, the ratio of 
the voting rights of the corporation after the combination which will be 
owned by the shareholders of each party company as corresponding 
voting rights must be the same as before, and it must be within the 
scope of 45% to 55%. 
Thirdly, no fact which indicates a relationship of control other than the 
ratio of the voting rights must exist互
Also in the USA, the pooling of interest method has assumed business 
combinations where the shareholders of combining companies will 
become shareholders of combined companies. The essence of the 
pooling of interest method is not that the shareholders of the 
combining companies will withdraw assets or will make investment, 
but that they will exchange stocks at the same ratio at which they 
owned the combining companies. 
(3) Examination of the rules of the purchase method by FAS 
1) Exchange of stocks as capital combination (stock combination) 
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In accordance with the US accounting standards, a business 
combination will occur when more than two entities are combined into 
one entity, and there are two types, one of which is asset combination 
and the other of which is capital combination (stock combination). 
An asset combination is a result where one company acquires 
assets of more than two other companies, or a result where it is 
formed by one company acquiring assets of more than two existing 
companies. 
In an asset combination, a purpose company will cease to exist as 
an entity, and will become either a liquidation company or an 
investment company. Acquisition of a capital combination (stock 
combination) will occur when one company acquires 50% of more of 
the stocks with voting rights in issue of one or more than one purpose 
companies, or when a new company will acquire a controlling interest 
of the stocks with voting rights in issue of more than one purpose 
company. 
2) Decision process of the acquiring entity 
For the purpose of the application of FAS141, a business 
combination will occur when an entity acquires the shareholders' 
equity interest or net assets comprising the business of one or more 
than one entities, and acquires the control over these other entities9. 
Business combinations will take a number of different forms, as 
FAS141 may be applied to combinations which include mergers or 
non-mergers. 
An entity or a number of entities will merge or become subsidiaries 
in a business combination. Otherwise, an entity will transfer its interest 
or its holders will transfer their interests. Furthermore, al entities will 
transfer its net assets or the holders of these entities will transfer their 
interests in shareholders equities to the newly formed interests⑲ 
All business combinations to be made in accordance with FAS141 
should be accounted for under the purchase method九
The first stage where the purchase method is applied is to decide 
the acquiring entity. All appropriate facts and environments have 
factors for consideration when deciding the acquiring entity匹
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(a) The acquiring entity will have voting rights corresponding to 
those of the combined companies after the combination. It is a 
company where the holders will remain or a company which 
will receive a greater part of the voting rights. 
(b) The acquiring entity will have a major minority interest with 
voting rights, when other holders or an organized group of 
holders have an important interest of voting rights. 
(c) The acquiring entity is a combining company where the 
holders or the controlling body has the ability to control and/or 
govern the majority of the voting rights of the controlling body 
of the combined business. 
(d) The acquiring entity is a combined company where senior 
managers execute controlling power on that combined 
company. 
(e) The acquiring entity is a combining company which will pay a 
premium over the market value of the equity interests of other 
combining companies or entities. 
(4) Examination of goodwill 
1) When does goodwill occur? 
Acquired assets will be recorded at a fair market value. The 
premium of the acquired price, which is the fair market value of 
acquired assets less an amount of succeeded liabilities will be 
recorded as goodwill. Accounting of the goodwill thus recorded will be 
treated in accordance with FAS-142 (Goodwill and Intangible Assets). 
The total of the assets acquired at market value higher than the cost 
and the market value allotted for the succeeded liabilities may exceed 
the consideration of the acquired company. The amount of the excess 
obtained, where the total of (a) financial assets excluding investment 
treated under the equity method, (b) disposal by sale, (c) deferred 
income tax, (d) prepaid assets relating to pensions and other 
retirement pension plans, (e) other current assets, and others is 
reduced to zero, will be recognized as abnormal profits. These 
abnormal profits are generally recognized for the period while the 
business combination is completed. 
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2) Examination of reasonability of impairment loss and write-off of 
goodwill 
In business combination accounting, when a parent company 
acquires the stocks of its subsidiary and the acquiring cost of the 
stocks of the subsidiary of the parent company is greater than the net 
assets (book value) of the subsidiary, the amount of the difference can 
be explained in the form of land revaluation profit or goodwill. This 
means that goodwill occurs only in the purchase method. Next, where 
the acquiring cost of stocks of the subsidiary is smaller than the 
interest of the parent company in the net assets (book value) of the 
subsidiary, revaluation of assets does not normally occur. In this case, 
a negative goodwill occurs. However, if the goodwill is a negative 
amount, a profit will occur when it is written off every term, but no 
write-off is made in accordance with the FASB. 
3) Impairment loss of the goodwill 
Where the amount of the cost of the acquired company exceeds 
an amount allotted for the acquired assets and the succeeded 
liabilities, the excess will be recognized as the goodwill. Such a 
recorded goodwill will be treated in accordance with FAS-142 (Goodwill 
and Other Intangible Assets) in the USA. 
Writing off goodwill is not allowed in FAS-142. A test of goodwill 
impairment loss must therefore be carried out. When the following 
impairment loss occurs, an impairment loss must be accounted for. 
Firstly, goodwill is not written of, but a test will be carried out for 
the reported level which has been referred to as the reporting unit13. 
Secondly, the reporting unit is an operating segment as defined in 
FAS131 (Disclosures about Segments of an Enterprise and Related 
Information) 14 
Thirdly, an impairment loss occurs, when a remarkable decline in 
market share of the reporting unit is expected as a result of an 
introduction of new products, new technology or new service by 
competitors, or when a downward revision much lower than its 
estimated sales and profits in the reporting unit caused by factors of 
change in technology, loss due to a large fal in customers, 
intensification of competition, etc., or a recovery is impossible as a 
result of a downward revision much lower than its estimated profits or 
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declines in cash flow due to an unexpected increase in costs. 
In addition, goodwill is not allowed to be written off also in IASB. 
Instead, an impairment loss test must be carried out where there is an 
indication of an impairment loss because of a phenomenon or a 
change in the situation every year in accordance with IAS36. 
Next, we set out below our counterarguments against impairment 
of goodwill. 
Firstly, the effect accompanied by the occurrence of goodwill 
comes not only from the merged company, and should therefore be 
measured by the synergy effect by the efforts made by the party 
companies of the merger. In reality, goodwill created by themselves 
after the merger has occurred. It is therefore difficult to recognize the 
goodwill created by the synergy in the state of the going concern. 
Secondly, despite that, if the accounting treatment of goodwill in 
the state of the going concern is only the treatment of impairment 
loss, and if the merger continues to succeed,・the goodwill which 
occurs at the time of the merger will not be subject to the treatment of 
impairment loss, but will continue to be shown as an asset in the 
balance sheet. In reality, it is reasonable to understand that 
impairment loss is not treated so that new self-created goodwill may 
not occur, after the actualization of the latent profit at the time of the 
merger. 
Thirdly, in more detail, goodwill which occurs at the time of the 
merger will usually deteriorate because of the obsolescence of 
technological innovation, managerial knowhow and business system. 
Unless it is written off on a regular basis, it will be in the state where 
obsolete intangible fixed assets are owned as in the state where 
obsolete inventories are owned. 
4) Write-off of goodwill in Japan 
In the case of Japan, where the acquired cost exceeds the net 
amount allotted to the acquired assets and the succeeded liabilities, 
the amount of that excess will be accounted for under assets as 
goodwill, and where it is lower, the amount of the shortfall will be 
accounted for under liabilities as a negative goodwill. In this case, a 
negative goodwill will also be accounted for. Goodwill is written off on 
a regular basis in a straight line method for a period of 20 years or 
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less in which it is effective, or any other reasonable method. On the 
other hand, if a negative goodwill is written off, it is possible to account 
for a profit. An environment to manipulate profits can therefore be 
created. 
3. Stock transfer -Daiichi Sankyo Company, Limited. -
(1) Summary of stock transfer under the Japanese standards 
This is a procedure to establish a relationship between a parent 
company and its wholly owned subsidiaries by the shareholders of the 
existing companies (two companies, i.e., Sankyo Company, Limited 
and Daiichi Pharmaceutical Co., Ltd.) transferring stocks to Daiichi 
Sankyo Company, Limited. (the holding company) which was 
established on September 28, 2005. The wholly owning parent 
company (Daiichi Sankyo Company, Limited) issue, in place of 
acquiring stocks of Sankyo Company, Limited and Daiichi 
Pharmaceutical Co., Ltd., new stocks corresponding to them and 
deliver them to the shareholders of the two original companies. As a 
result, Sankyo Company, Limited and Daiichi Pharmaceutical Co., Ltd. 
will become wholly owned subsidiaries of Daiichi Sankyo Company, 
Limited. 
Firstly, the class of the stocks issued by the wholly owning parent 
company at the time of stock transfer is common stocks of 
771,498,064. This is calculated on the basis of the number of shares 
in issue by these two wholly owned subsidiaries as at March 31, 2005 
(on the number of share calculation base date). Regarding the ratios 
of stock transfer, 1 share of Sankyo Co., Ltd. was exchanged for 1 
share of Daiichi Sankyo Company, Limited, and 1 share of Daiichi 
Pharmaceutical Co., Ltd. was exchanged for 1.159 shares of Daiichi 
Sankyo Company, Limited. Accordingly, the total was 735,011,343 
shares comprising 439,498,765 shares, which is the number of shares 
in issue of Sankyo as at the number of share calculation base date, 
times 1 and 286,453,235 shares, which is the number of shares in 
issue of Daiichi Pharmaceutical Co., Ltd. times 1.159固
Secondly, the paid-in capital of the wholly owning parent company is 
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the paid-in capital of 50,000 million yen approved at the general 
shareholders'meeting. The price of the stocks of the subsidiaries will 
equal to the total amount of the net assets of the two wholly-owned 
subsidiaries. 
Thirdly, the capital reserve of the newly formed wholly owning parent 
company is the amount obtained by subtracting the total amount of 
the paid-in capital and stock purchase grant from the total amount of 
net assets of the wholly owned subsidiaries as at the stock transfer 
day. However there are different theories concerning an amount of net 
assets of a wholly owned subsidiary. They are that "the confirmation 
of net assets existing at the company which will become a wholly 
owned subsidiary on the stock exchange date shall depend not only 
on the confirmation of the amount of properties succeeded from the 
extinguishing company in cases of a merger but also on the 
development of fair accounting practice"16 and that "at the time of the 
stock exchange where a company with liabilities exceeding assets will 
be made a wholly-owned subsidiary, revaluation of the assets of 
companies which will become two wholly-owned subsidiaries is 
allowed. If the state of liabilities exceeding assets is resolved as a 
result, stock exchange may take place" .17 According to the fair 
accounting practice of the former, the net assets will be stated at book 
values, and in the latter case, they will be stated at market value. In 
this case, capital reserves will be an amount obtained by subtracting 
the total amount of the paid-in capital and the stock purchase grant 
from the total amount of net assets of the two wholly owned 
subsidiaries as at the stock transfer date. The amount is calculated to 
be・1,083,349 million yen, adopting the former theory固
(2) Exchange ratio 
The stocks of Sankyo Company, Limited owned by the 
shareholders of Sankyo Company, Limited will be transferred to a 
wholly-owning parent company (Daiichi Sankyo Company, Limited.), 
and the shareholders of the company which will become its wholly-
owned subsidiary (Sankyo Company, Limited) will become 
shareholders of the wholly-owning parent company (Daiichi Sankyo 
Company, Limited) by receiving allotment of stocks issued by the 
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wholly-owning parent company (the Daiichi Sankyo Company, 
Limited.) at the time of its stock tran$fer. The stock exchange ratio is 1 
common stock of Sankyo Company, Limited for 1 common stock of 
Daiichi Sankyo Company, Limited and 1 common stock of Daiichi 
Pharmaceutical Co., Ltd. for 1.159 common stocks of Daiichi Sankyo 
Company, Limited. We will examine its reasonability. 
In this case, following are the grounds (Daiichi Sankyo Company, 
Limited.) for the SEC merger ratio:-
1) Comparison of the market capitalization of the stocks 
The market capitalization of the stocks (Sankyo Company, Limited) 
(High @2,505 yen and low 1,957yen during Jan. to July 2004, the 
number of shares in issue being 439,498 thousand) 
The market capitalization of the stocks (Daiichi Pharmaceutical Co., 
Ltd.) (High @2, 110 yen and low 1. 734 yen during Jan to July 2004, 
the number of shares in issue being 286,453 thousand) 
(3) Disposal of own stocks 
To comply with the Commercial Code of Japan, Daiichi Pharmaceutical 
Co., Ltd. and Sankyo are required to dispose the stocks of Daiichi 
Sankyo Company, Limited. which they receive as stock transfer as the 
holders of stocks of the other party within a scope of a reasonable 
period after the stock transfer. As at March 31, 2005, Daiichi 
Pharmaceutical Co., Ltd. has 2,602,000 common stocks of Sankyo 
and Sankyo has 2,864,000 common stocks of Daiichi Pharmaceutical 
Co., Ltd .Daiichi Pharmaceutical Co., Ltd. owns approximately 0.3% 
of the common stocks of Daiichi Sankyo・and Sankyo owns 
approximately 0.4% in accordance with the stock transfer immediately, 
on the assumption of non-conversion of such stock holding at the 
agreed conversion ratio. Because these stocks are re-acquired 
through a re-purchase of non-market stocks or through a method 
allowed by other law, they will be disposed as market transactions 
through the Tokyo Stock Exchange on which Daiichi Sankyo 
Company, Limited. is listed. Even if Daiichi Pharmaceutical and 
Sankyo recommend to dispose of their interests in Daiichi Sankyo, the 
stock disposal will affect the general market price of the Daiichi 
Sankyo stocks. 
30 
4. Difference between the accounting standards of Japan and the 
USA 
We will examine the stock transfer of the business combination, 
assuming that it was carried out under the purchase method in 
accordance with the US accounting standards. 
(1) Daiichi Pharmaceutical Co., Ltd. 
1) Consolidated income statement 
When we examine the difference between the accounting 
standards of Japan and the USA in the case of Daiichi Pharmaceutical 
Co., Ltd., net income for the year ending March 2003 is 25.6bn yen 
under the US standards, which is 12.0bn yen greater than 13.Sbn yen 
under the Japanese standards. Net income for the year ending March 
2004 is 30.7bn yen under the US standards, which is, 4.0bn yen 
greater than 26.6bn yen under the Japanese standards. 
2) Consolidated balance sheet 
When we examine the difference in the balance sheet of Daiichi 
Table 1 the difference in the accounting standards between Japan and the 
USA. (Daiichi Pharmaceutical Co., Ltd.) 
Daiichi P/L 
Income Statement Data(million of yen) 
Net Sales 
Cost of sales 
Selling,general and administrative expenses 
Research and development expenses 
Operating income 
Other (expenses) income 
Income before income taxes and minority interests 
Net income 
Per shar Datae 
Net income , basic 
Net income , dutiied 
Cash dividends per share 
U.SGAAP 
For the year Ended 
2003 
321,926 
106,955 
106,859 
55,505 
52,607 
-4,549 
48,058 
25,601 
92.25 
92.25 
30.00 
March 31, 
2004 
322,297 
106,475 
107,869 
59,718 
48,915 
2,147 
51,962 
30,736 
112.79 
112.79 
30.00 
Income Statement Data(million of yen) 
Net Sales 
Cost of sales 
Selling,general and administrative expenses 
Research and development expenses 
Operating income 
Other (expenses) income 
Income before income taxes and minority interests 
innet income of consolidated subsidiaries 
Net income 
Per shar Datae 
Net income , basic 
Net income , dutiied 
Cash dividends per share 
Japanese 
For the year Ended 
2,003 
322,011 
106,904 
109,093 
53,377 
52,637 
-16,353 
36,284 
13,567 
48.15 
30.00 
GAAP 
March 31, 
31 
2004 
322,767 
103,474 
114,129 
59,049 
46,115 
1,493 
47,608 
26,662 
97.25 
97.23 
30.00 
Pharmaceutical Co., Ltd. under the accounting standards of the USA 
and those of Japan, the minority interest for the year ending March 
2003 amounts to 397. 7bn yen under the US standards, which is 
smaller . by 3. 7bn yen than 401.4bn yen under the Japanese 
standards. The corresponding figure for the year ending March 2004 
under the US standards amounts to 422.4bn yen, which is greater by 
300million yen than 422.1 bn yen under the Japanese standards. 
Table 2 
Daiichi B/S 
Balanse Sheet Data(million of yen) 
Current assets 
Total assets 
Current Liabilities 
Total Liabilitis 
Total shareholders'equity 
Number of shares as adjusted to reflect in capital 
Authorized 
Outstanding 
Treasyry stock 
U.S GAAP 
For the year Ended 
2003 
307,220 
540,251 
83,036 
136,726 
397,719 
789,000,000 
275,209,858 
11,243,377 
March 31, 
2004 
291,643 
550,569 
79,153 
123,847 
422,406 
789,000,000 
269,700,226 
16,753,009 
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Balanse Sheet Data(million of yen) 
Current assets 
Total assets 
Current Liabilities 
Total Liabilitis 
Total shareholders'equity 
Number of shares as adjusted to reflect in capital 
Authorized 
Issued 
Treasyry_ stock 
(2) Sankyo 
1) Consolidated income statement 
Japanese 
For the year Ended 
2003 
289,155 
512,384 
75,358 
104,468 
401,472 
789,000,000 
286,453,235 
11,243,377 
GAAP 
March 31, 
2004 
283,206 
521,809 
71,536 
94,719 
422,130 
789,000,000 
286,453,235 
16,753,009 
When we examine the difference between the accounting 
standards of Japan and the USA in the case of Sankyo, net income 
for the year ending March 2003 is 34.9bn yen under the US 
standards, which is 1.0bn yen greater than 33.8bn yen under the 
Japanese standards. Net income for the year ending March 2004 is 
38.2bn yen under the US standards, which is smaller by 5.2bn yen 
than 43.4bn yen under the Japanese standards. 
2) Consolidated balance sheet 
When we examine the difference in the balance sheet of Sankyo 
under the accounting standards of the USA and those of Japan, the 
minority interest for the year ending March 2003 amounts to 646.2bn 
yen under the US standards, which is smaller by 12.4bn yen than 
658. ?bn yen under the Japanese standards. The corresponding figure 
for the year ending March 2004 under the US standards amounts to 
666.0bn yen, which is smaller by 16.5bn yen than 682.6bn yen under 
the Japanese standards. 
33 
Table 3 the difference in the accounting standards between Japan and the 
USA. (Sankyo) 
sankyo P/L 
Income Statement Data(million of yen) 
Net Revenue 
Cost of sales 
Selling,general and administrative expenses 
Research and development expenses 
Gain on sale of property ,Plant and equipment.net 
Operating income 
Other (expenses) income 
Income before income taxes and minority interests 
Income from cotinuing operations 
Loss (gain)from discontinued operations 
Net income 
Per shar Datae 
Bsaic Net income ,per common share 
Dutied Net incomeper shared 
Cash dividends declared 
Income Statement Data(million of yen) 
Net Sales 
Cost of sales 
Selling,general and administrative expenses 
Research and development expenses 
Operating income 
Other (expenses) income 
Income before income taxes and minority interests 
Net income 
Per shar Datae 
Bsaic Net income ,per common share 
Dutied Net incomeper shared 
Cash dividends applicable to year 
U.S GAAP 
For the year Ended 
Japanese 
2003 
576,270 
233,067 
178,432 
84,453 
80,318 
-2,510 
77,808 
34,941 
90 
34,851 
78.97 
78.97 
25.00 
For the year Ended 
2,003 
569,927 
228,754 
174,673 
86,662 
79,838 
-7,483 
72,354 
33,845 
75.85 
25.00 
March 31, 
GAAP 
March 31, 
2004 
601,273 
228,839 
194,004 
93,597 
84,833 
488 
85,321 
44,410 
6,199 
38,211 
87.43 
87.42 
30.00 
2004 
596,345 
221,653 
192,417 
86,720 
95,555 
-12,962 
82,592 
43411 
98.57 
98.56 
30.00 
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Table 4 
sankyo 8/S 
Balanse Sheet Data(million of yen) 
Current assets 
Total assets 
Current Liabilities 
Total Liabilitis 
Total shareholders'equity 
Number of shares as adjusted to reflect in capital 
Authorized 
Outstanding 
Treasyry stock 
Balanse Sheet Data(million of yen) 
Current assets 
Total assets 
Current Liabilities 
Total Liabilitis 
Total shareholders'equity 
Number of shares as adjusted to reflect in capital 
Authorized 
Issued 
Trea~_yry stock 
U.S GAAP 
For the year Ended 
2003 
556,910 
933,350 
173,335 
276,394 
646,234 
1,178,099,000 
439,326,264 
10,172,501 
Japanese GAAP 
For the year Ended 
2003 
546,039 
915,792 
154,985 
248,703 
658,707 
1,178,099,000 
449,498,765 
10,172,501 
5. Provisional accounting with revaluation 
March 31, 
2004 
546,449 
940,004 
173,637 
262,960 
666,027 
1,168,099,000 
429,542,651 
9,956,114 
March 31, 
2004 
535,816 
927,244 
154,758 
235,806 
682,594 
1, 168,099,000 
439,498,765 
9,956,114 
(1) Decision of costs under the US accounting standards 
1) Basic matters 
Decision of acquiring costs by the acquiring entity is the same as 
that of individual costs of acquired individual assets. Cash payment is 
used by measuring the costs of the acquired entity. Similarly, valuation 
at market value is decided to be used for the purpose of using the fair 
value of assets and the fair value of succeeded liabilities allotted as a 
consideration 19 to measure the costs of the acquired entity. If the 
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allotted market price is not equal to the market value of the interest 
securities, and even if measuring a fair value of succeeded net assets 
is directly impossible, the consideration which should be received will 
be evaluated. The amounts in which both net assets received 
including goodwill and the allotted market value of stocks in issue are 
recorded must be carefully decided. Independent valuation is useful 
as valuation at the market value as it is used to help one decide 
market value of securities20 which will be issued. 
2) Examination of acquired assets and succeeded liabilities21 
Allotment of the estimated purchase price is recorded to reflect 
differences between the book values and market values. In addition, 
the occurrence of the cost amounting to 2,000 million yen of the 
estimated transaction of Sankyo is recorded. The following adjustment 
will be made to record the allotment of the estimated purchase price 
to reflect differences between the book values and market values of 
acquired assets and succeeded liabilities. [Reference: the provisional 
adjustment symbol of the provisional combined balance sheet and 
income statement. 
a. Inventory (raw materials): an increase of 10,000 million yen of 
inventories at recent re-procured prices. 
Final products and merchandise will be revalued by estimated sale 
prices less costs at which they are disposed of and reasonable profit 
allotment, and work in process will be revaluated by estimated sale 
prices less costs at completion, costs at which they are disposed of 
and reasonable profit margin. 
b. Tangible fixed assets: an increase of 33,000 million yen 
Real estate to be used will be revalued at a recent re-procured price, 
and the real estate for sale is at market value less cost for sale. For 
example, land, natural resources and non-market securities will be 
revalued at estimated values. 
c. Intangible fixed assets: 
As a result of the allotment of the estimated purchase price, other 
intangible assets were recorded at 338.0bn yen. They comprised 
mainly completed technologies of 297.0bn yen and patents of 41.0bn 
yen. 
9. 7 years, which is the estimated useful life of these various 
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completed technologies related to the estimated value of other 
intangible assets, 5.3 years, which is the estimated useful life of 
patents, and their respective depreciation costs of 19,000 million yen 
and 38,000 million yen will be recorded at the end of the six months 
period ending on September 30, 2004 and at the end of the business 
year on March 31, 2004. 
If an intangible fixed asset occurs as a result of a contractual or 
any other legal right, it will be separated from goodwill and recognized 
as an asset. If this condition is not agreed, the intangible fixed asset is 
recognized as an asset, if it can be separated (For example, if it is 
possible to sell, transfer, give a license, rent or exchange). 
Incorporated labor cannot be recognized, separated from goodwill. 
d. Research and development expenses: it was an increase of 
89,000 million yen, and was accounted for under the debit as retained 
profit. 
e. Tax effect: The tax effect of allotment of the purchase price and 
the deprecation costs of other intangible assets are recognized as an 
increase of deferred tax liabilities by 156,210 million yen which are 
included in other long-term liabilities. 
f. Retirement pension and retirement money cost: an increase of 
18,161 million yen. 
18,161 million yen of unrecognized items of Daiichi Pharmaceutical 
Co., Ltd. comprises the actual unrecognized loss of 18,148 million 
yen, unrecognized previous service cost of -1,060 million yen, 
unrecognized transition liabilities of 373 million yen, in accordance 
with the accounting for FAS141 Business combinations. Where a 
defined benefit pension plan of a single employee is acquired as part 
of a business combination, the excess of a projected benefit obligation 
under the system, which is an excess of the pension asset, is 
recognized as a liability, and the excess of a pension asset, which is 
an excess of the projected benefit obligation under the system, is 
recognized as an asset. As a result, (a) existing unrecognized net 
profit or loss, (b) unrecognized previous service cost, and (c) 
elimination of unrecognized net obligation or net asset, existing on the 
first application date of FAS87 will take place. For the following period, 
the difference between the net pension cost of the acquisitor and the 
premiums will reduce net liabilities or net assets recognized on the 
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day on which the business combination took place to the extent that 
the previously unrecognized net profit or loss, unrecognized previous 
service cost or unrecognized benefit obligation will be considered to 
decide an amount of the premiums of the pension. In addition, the 
acquisitor will calculate the effect of an expected termination or a 
reduction of the pension to calculate an amount of a projected benefit 
obligation under a system on the day on which the business 
combination takes place匹
The requirements for retirement monies and retirement benefits other 
than pensions prescribed in FAS 106 (Employer's Accounting for 
Postretirement Benefits other than pensions) are the same. 
3) Adjustment on profit and loss 
a. Recognition of market value of bonus reserve on the basis of 
stocks. 
Sankyo will calculate a bonus plan on the basis of the stocks under 
the recognition and measurement rules in accordance with APB25 
(Accounting for Stock Issued to Employees). Sankyo will record bonus 
expenses for stock options which vary easily under the pension 
accounting. Daiichi Pharmaceutical Co., Ltd. will calculate concerning 
the bonus plan on the basis of stocks for directors and employees 
using the market value method prescribed in FAS 123. 
Where Daiichi Pharmaceutical Co., Ltd. applies the intrinsic value 
on the basis of the method of APB25, for the purpose of calculating 
the bonus on the basis of the stocks, the bonus expenses on the 
basis of the stocks for six months ending September 30, 2004 will 
become 7,790 million yen, and will decline by 85 million yen and 161 
million yen without a tax effect at the period ending September 30, 
2004 and at the period ending March 31, 2004 respectively. 
b. Relevant write-offs including research and development 
expenses: 
R&D expenses declined by 310 million yen and 620 million yen for 
the six months ending September 30, 2003 and for the year ending 
March 31 , 2004 respectively. 
c. Retirement money and retirement pension: 
Concerning the amount expected to be deleted and recorded as 
unpaid pension service costs through the allotment of the purchase 
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price, the cost of net pension for a definite period included in cost of 
goods sold is likely to fal by 502 million yen at the end of the six 
months period ending September 30, 2004 and by 903 million yen at 
the end of the year ending March 31, 2004 respectively. On the other 
hand, those, which are included in selling and general administrative 
expenses, will fal by 56 million yen and 100 million yen respectively. 
d. Tax effect of adjustment of provisional results: an increase in 
deferred tax assets of 9,491 million yen as at September 30, 2004, 
and increases of 353 million yen and 662 million yen in corporation 
tax expenses at the end of the six months period ending September 
30, 2004 and at the end of the year ending March 31, 2004 
respectively. 
e. Depreciation costs of other intangible assets: These are 
included in selling costs relating to completed technologies which 
Daiichi Pharmaceutical Co., Ltd. and Sankyo will use to produce 
profits. 
f. Corporation tax: A fal in corporation tax by 7,790 million yen for 
the six months ending September 30, 2004 and by 15,580 million yen 
for the year ending March 31, 2004 respectively. 
g. Cost of corporation tax effect: an increase of 148,806 million yen 
Daiichi Pharmaceutical Co., Ltd. and Sankyo have developed a 
business plan to integrate the business of these to companies. 
118.0bn yen of temporary integration costs will be expected for the 
year ending March 31, 2007, on the basis of these recent discussions. 
Approximately 80% of these costs are estimated to be, for example, 
payment for retirement on recommendation and other human related 
cost items such as transfer of people. It is expected that the parties 
concerned will recognize a substantial cost cut to reduce an annual 
cost of 50.0bn yen for the business year ending March 31, 2008 with 
respect to the increase of 57.0bn yen estimated for the year ending 
March 31, 2010. 
These reductions are expected to reduce both human expenses in 
the domestic medical goods business and other operating expenses. 
Even if this recent plan reflects recent management expectations, it is 
impossible to assume that these expectations will guarantee their 
occurrence. The company's integration plan is stil continuing to 
completely combine the existing medical good business of Daiichi 
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Pharmaceutical Co., Ltd. and Sankyo, and make them sophisticated 
and detailed integration procedures including the method of abolishing 
other businesses which have not yet been decided. These integration 
costs and expected saving are not therefore reflected in these 
unaudited provisional financial statements. 
(2) Stock transfer transactions 
1) Shareholders'interest in Daiichi Pharmaceutical Co., Ltd. 
The book value balance of al the accounts (paid-in capital of 
common stocks of 45,247 million yen, capital reserve of 50,212 million 
yen, retained profit of 312,198 million yen (after the elimination of own 
stocks of 38,831 million yen, previously acquired goodwill and other 
intangible assets of 8,946 million yen), cumulative other 
comprehensive income of 14,448 million yen) of the shareholders' 
interests of Daiichi Pharmaceutical Co. Ltd. will be eliminated, and the 
purchase price of common stocks of Daiichi Pharmaceutical Co., Ltd. 
being 744,46;2 ;million yen will be recorded as the paid-in capital of 
common stocks being 50,000 million yen and the capital reserve of 
694,462 million yen respectively. 
2) Shareholders'interests in Sankyo 
The book value balance of paid-in capital of common stocks of 
Sankyo (68,793 million yen) will be transferred to the capital reserve. 
3) Adjustment of own stocks 
On the transfer of stocks in combination, own stocks (20,363 
million yen) owned by Sankyo and own stocks (38,831 million yen) 
owned by Daiichi Pharmaceutical Co., Ltd. will be eliminated by 
offsetting with retained profits before the completion of the stock 
transfer on combination on September 30, 2005. Sankyo stocks of 
6,063 million yen owned by Daiichi Pharmaceutical Co., Ltd. and the 
Daiichi Pharmaceutical stocks of 5,433 million yen owned by Sankyo 
which are included in investments in the historical financial statements 
dated September 30, 2004 will be exchanged for stocks of Daiichi 
Sankyo Company, Limited on the completion of the stock transfer on 
combination. Accordingly, these stocks amounting to 11,496 million 
yen in total will be reclassified from the investment account to own 
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stocks by valuing them at cost. 
4) Adjustment of cash payment to shareholders 
In the stock transfer on combination, Sankyo shareholders will 
receive 25 yen in cash per Sankyo share, and Daiichi Pharmaceutical 
shareholders will receive 25 yen in cash per Daiichi Pharmaceutical 
share from Daiichi Sankyo Company, Limited. The estimated total 
amounts that should be paid to Sankyo shareholders and Daiichi 
Pharmaceutical shareholders will be 10,738 million yen and 6,711 
million yen respectively, and the respective relevant cash payments 
will be recorded in the provisional balance sheet. 
5) Exchange ratio 
Temporary combination basics for each period shown and diluted 
income per share are based on the combination basics and the 
average diluted number of shares of Sankyo and Daiichi 
Pharmaceutical Co., Ltd. Historical combination basics and the 
average diluted number of shares of Daiichi Pharmaceutical Co., Ltd. 
will be converted at the ratio of 1 common stock of paid-in capital of 
Daiichi Pharmaceutical Co., Ltd. for 1.19 shares of Daiichi Sankyo 
Company, Limited. 
6. Examination of accounting aspects of the purchase method 
and the pooling of interest method 23 
(1) Contents of treatment under the purchase method 
The registration and occurrence of the interest securities in the 
business combination calculated under the purchase method will be 
reduced from the fair value of securities. The succeeded direct costs 
are treated as a consideration and are included in the acquired total 
cost. The acquired liabilities for expenses to close factories and 
unperformed obligations are the direct costs for acquisition, and are 
recorded at the present value of the amount that should be paid. The 
direct cost includes only succeeded cash payments by occurring in 
the business combination. These include remunerations and 
accounting of finderers, legal service, technological evaluation and 
consulting fees for appraisal. Internal costs succeeded in the business 
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Table 5: Provisional combined balance sheet 
Conde need combined Balance Sheets 
September 30,2004 
million of yen 
sankyo Daiichi Proforma Proforma 
adjustmentt combined 
Assets 
Current assets: 
Cash & Cash equivalents 249,333 73,123 ー17,449 305,007 
Short-term investments 60,153 66,845 126,998 
Accouts receivable,less allowance for doubtful 147,527 83,166 230,693 
accounts 
Inventories 93,829 38,118 10,000 141,947 
Deferred income taxes 26,990 19,695 46,685 
Other current assets 12,070 10,560 22,630 
Total current assets 589,902 291,507 —7,449 873,960 
Investments and advances 109,848 103,800 —11,496 202,152 
Property ,Plant and equipment,less 216,238 106,618 33,000 355,856 
accumulated depreciation 
Goodwill 3,091 5,914 28,035 31,126 
—5,914 
Other intangibles.net 25,145 24,217 338,000 382,243 
—5,119 
Other assets 21,452 15,002 9,491 45,945 
Total assets 965,676 547,058 378,548 1,891,282 
Liabilities and Shareholders'equity 
Short-term borrowings,including current portion 17,946 2,111 20,057 
of long term debt 
Accounts payable 48,826 29,632 78,458 
Accrued income taxes 20,506 9,572 30,078 
Other current liabilities 83,559 33,148 2,000 118,707 
Total current liabilities 170,837 74,463 2,000 247,300 
Long-term debt 6,802 2,505 9,307 
Accrued pension and severance costs 74,829 33,087 18,161 126,077 
Other Long-term debt 9,277 4,109 156,210 169,596 
Total noncurrent liabilities 90,908 39,701 174,371 304,980 
Minority interests 11,066 1,843 12,909 
Shortholders'equity 
Common stock 68,793 45,247 -64,040 50,000 
Additional paid-in capital 67,263 50,212 713,043 830,518 
Retained earnings 566,760 359,975 -89,000 446,659 
—371,392 
-8,946 
—10,738 
Accumulated other comprehensive income 10,412 14,448 —14,448 10,412 
Treasury stock ,at cost ー20,363 -38,831 59,194 ー11,496
—11,496 
Total shareholders'equity 692,865 431,051 202,177 1,326,093 
Totalliabilities and shareholders'equity 965,676 547,058 378,548 1,891,282 
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Table 6: Provisional combined income statement 
Proforma Conde need combined Statement of Income 
(million of yen) sankyo Daiichi Proforma 
March 31,2004 adjustmentt 
Net revenue 601,273 322,977 924,250 
Cost of sales 228,839 106,475 38,000 372,411 
-903 
Research and development expenses 93,597 59,718 -620 152,695 
Selling,general and administrative expenses 194,004 107,869 -161 301,612 
-100 
Other (expenses) income 488 2,147 2,635 
Income from cotinuing operations befaore 85,3i1 51,062 -36,216 100,167 
income taxes and minority interests 
lncone taxes 40,397 21,812 -15,580 47,291 
662 
Minority intersts 514 -1,486 -972 
Income from cotinuing operations 44,410 30,736 -21,298 53,848 
Income from cotinuing operations per common share: 
Basic 101.61 112.79 12.09 
Diluted 101.60 112.79 72.08 
Weighted average share used to calculate 
earnings per common share amounts {Thounds 
of shares): 
Basic 437,053 272,516 37,409 746,978 
Diluted 437,099 272,516 37,409 747,024 
Cash dividends per share 25.00 30.00 
combination calculated under the purchase method will become 
expenses as succeeded. 
The number of common stocks in issue of Daiichi Pharmaceutical 
Co., Ltd. as at September 30, 2004 (in 1,000) 268,421 
The exchange ratio x 1 .159 
311,100 
The average market price of Sankyo two days after the accounting 
date (February 25, 2005) on which the stock transfer was 
announced times: 
(in million yen) 
The announcement day of the stock transfer @2,393 744,462 
Estimated transaction cost 2,000 
Estimated purchase price 746,462 
Estimated purchase price (in million yen) 
Book value of acquired assets 
Cancellation of the actually existing goodwill (1) 
Tax effect 
Cash paid in relation to stock transfer on combination 
Adjusted book value of acquired net assets 
What shou Id be allotted: 
Increase in inventories at market value 
Increase in tangible fixed assets at market value 
Increase in intangible fixed assets at market value (2) 
R&D in process (3) 
Cancellation fee of unpaid benefit pension contract (4) 
Tax effect 
Goodwill (5) 
Expected purchase price 
1) Cancellation of the existing goodwi1124 
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431,051 
(11,033) 
2,087 
(6,711) 
415,394 
10,000 
33;000 
338,000 
89,000 
(18,161) 
(148,806) 
28,035 
746,463 
Regarding deletion of goodwill, the goodwill that Daiichi 
Pharmaceutical Co., Ltd. acquired previously amounting to 5,914 
million yen and the intangible fixed assets amounting to 5,119 million 
yen as at September 30, 2004 were deleted. These deletions were 
recorded under debit as retained profit in the amount after tax. 
Retained profit therefore declined by 8,946 million yen. 
2) Relevant write-offs included in R&D expenditures 
310 million yen and 620 million yen are reduced for the period of 
six month ending September 30, 2004 and for the year ending March 
31 , 2004 respectively. 
3) Completed intangible assets 
These assets represent completed technologies, core technologies 
and patents. Their contents are completed technologies of Daiichi 
Pharmaceutical Co., Ltd. and, the individual products have not been 
completed. Instead, 338,000 million yen of intangible assets included 
in the provisional financial data with respect to various products were 
decided within Daiichi Pharmaceutical Co., Ltd. on the basis of 
estimated revenue and operating income of products and a wide 
range of the company's own experience in the medical goods industry. 
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If the final valuation expected to be completed within 6 to 12 months 
from the completion of the stock transfer does not produce 338,000 
million yen, we estimate that recognizable assets will be adjusted to 
be made such values四
4) R&D expenses in process 
As required by FAS4 (Financial Accounting Standard Board 
Interpretation) N04""Applicability of FASB"" Purchase method (FIN4), 
purchase prices allotted to R&D in process will be immediately made 
costs. This is not sufficient information to provide remedies in relation 
to individual projects in process. A compound-by-valuation of Daichi's 
in process research and development has not been performed. 
Instead, 89,000 million yen for the research and development in 
process which was included in part of the provisional financial data 
was valued on the amounts expensed for R&D activities together with 
the company's wide range of experiences and such other projects 
carried out by then, including potentially completed success cases of 
compounds at various stages, and markets for general and potential 
products of Daiichi Pharmaceutical Co., Ltd. and other knowledge 
concerning more valuable various kinds of products out of the product 
lines of Daiichi Pharmaceutical Co., Ltd. However, the compound 
calculation in accordance with FAS 141 does not guarantee that the 
valuation is definite. If the actual valuation estimated to be completed 
within 6 to 12 months from the completion of the stock transfer on 
combination is not 89,000 million yen, we consider that the evaluated 
amount of the expenses for the research and development in process 
will be adjusted to that amount. 
5) Recognition of unrecognized items under the pension accounting 
In accordance with the accounting for the purpose of FAS141, 
Business combinations, 18,161 million yen of unrecognized items of 
Daiichi Pharmaceutical Co., Ltd. comprises the actual unrecognized 
losses amount to 18,148 million yen, unrecognized previous service 
cost of -1,060 million yen, and unrecognized transition liabilities 
amounting to 373 million. Considering that retirement money and 
retirement pension are likely to be deleted and recorded as unpaid 
pension service costs through the allotment of the purchase price, we 
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estimate that net pension costs for the indefinite period which are 
included in cost of goods sold will fal by 502 million yen and 903 
million yen for the period of six months ending September 30, 2004 
and for the year ending March 31, 2004 respectively. These that are 
included in selling and general administrative expenses will decline by 
56 million yen and 100 million yen. 
(2) Accounting of goodwill 
The goodwill increased by 28,035 million yen under the purchase 
method. 
Conclusion 
Comparative studies between Japanese and US accounting are 
disclosed in annual reports and accounts of Sumitomo Electric 
Industry prepared because of the legend problems in the audit, and 
many of them have been disclosed in securities reports prepared as 
requested to show the causes of the differences between under the 
SEC standards and the Japanese standards. This study is a 
comparative study between Japanese and US accounting focusing on 
the purchase method and the pooling of interest method. Concerning 
the effect on the Japanese and the US tax affairs on the basis of the 
stock transfer of this case, we have already published a study26. So 
please refer to that study. 
(Professor of Accounting on the Commercial Studies Department of 
Kansai University) 
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